| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Clearance example | BRM-1420 (also referred to as GB3226) Acute myeloid leukemia (AML) — multiple genetic subsets (monotherapy and combination partners) | IND | — | Subscribe to access the data. | Small Molecules | Oncology | |
IND Clearance example | BRM-1420 (also referred to as GB3226) Acute myeloid leukemia (AML) — multiple genetic subsets (monotherapy and combination partners) | IND | — | Subscribe to access the data. | Small Molecules | Oncology | |
IND Clearance example | BRM-1420 (also referred to as GB3226) Acute myeloid leukemia (AML) — multiple genetic subsets (monotherapy and combination partners) | IND | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Galecto, Inc.$28.69
-0.06 (-0.21%)
D 34Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.73 B
EPS
-12.10
P/E Ratio
-
Value Trade
6.55 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
23.78 M
Operating CF
-20.60 M
Total Assets
535.44 M
Total Liabilities
23.84 M
Equity
511.60 M
-1.95 %
Week
24.2 %
1 Month
11.5 %
3 Month
999.23 %
6 Month
-88.23 %
5 Year
-92.35 %
All Time
Cash Data
Cash Position
532.90 M
Monthly Burn
6.87 M
Runway
75 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
231.69 K
52 Week Range
2.01 - 38.33
% held by Insiders
25.3 %
% held by Institutions
79.06 %
Enterprise Value
1.72 B
Total Shares
1.60 M
Short %
10.19 %
Float Shares
781.57 K
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-12-06 | GB3226 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-12-06 | GB3226 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-12-06 | GB3226 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
D34
Pipeline Score $114M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 47%
Micro Cap (rank 490 of 923)
Percentile RankGalecto, Inc. faces pipeline headwinds (34/100), with $284M risk-adjusted pipeline value, led by GB1211 in Metastatic Melanoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GB1211 Small molecule | Metastatic Melanoma | Phase 2 | NCT05913388 | 19% | $200M | RECRUITING | 92 | - | - | Feb 1, 2030 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
GB1211 | metastatic/advanced non-small cell lung cancer (NSCLC) | Phase 1b/2a | 2023-10-23 | In the GALLANT-1 trial, the combination of GB1211 at a dose of 100 mg twice daily with atezolizumab showed an objective response rate of 60% in patients with metastatic NSCLC after at least three weeks of treatment. Read More | Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial Read More | |
GB1211 | metastatic/advanced non-small cell lung cancer (NSCLC) | Phase 1b/2a | 2023-10-23 | In the GALLANT-1 trial, the combination of GB1211 at a dose of 100 mg twice daily with atezolizumab showed an objective response rate of 60% in patients with metastatic NSCLC after at least three weeks of treatment. Read More | Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial Read More | |
GB1211 | metastatic/advanced non-small cell lung cancer (NSCLC) | Phase 1b/2a | 2023-10-23 | In the GALLANT-1 trial, the combination of GB1211 at a dose of 100 mg twice daily with atezolizumab showed an objective response rate of 60% in patients with metastatic NSCLC after at least three weeks of treatment. Read More | Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GLTO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GLTO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How GLTO ranks across every disease it competes inCompetitive Position is a premium feature
See how GLTO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial